Ubs Group Ag Inventiva S.A. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Inventiva S.A. stock. As of the latest transaction made, Ubs Group Ag holds 27,448 shares of IVA stock, worth $147,395. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,448

Previous 708 3776.84%

Holding current value

$147,395

Previous $2,000 4250.0%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.94 - $3.89 $78,615 - $104,018	26,740 Added 3776.84%	27,448 $87,000
Q1 2025 May 13, 2025	SELL	$2.11 - $3.26 $1.28 Million - $1.98 Million	-608,537 Reduced 99.88%	708 $2,000
Q4 2024 Feb 14, 2025	BUY	$1.65 - $2.77 $1.01 Million - $1.69 Million	609,245 New	609,245 $1.3 Million
Q2 2024 Aug 13, 2024	BUY	$2.62 - $3.89 $27,528 - $40,872	10,507 Added 7399.3%	10,649 $31,000
Q1 2024 May 13, 2024	SELL	$3.27 - $4.7 $366 - $526	-112 Reduced 44.09%	142 $0
Q4 2023 Feb 09, 2024	BUY	$3.64 - $4.55 $924 - $1,155	254 New	254 $1,000
Q2 2023 Aug 11, 2023	BUY	$2.42 - $4.88 $82 - $165	34 New	34 $0
Q3 2022 Nov 10, 2022	BUY	$3.69 - $6.05 $1,073 - $1,760	291 Added 12.64%	2,593 $10,000
Q2 2022 Aug 10, 2022	BUY	$5.61 - $12.15 $5,750 - $12,453	1,025 Added 80.27%	2,302 $13,000
Q1 2022 May 16, 2022	BUY	$10.51 - $13.66 $7,756 - $10,081	738 Added 136.92%	1,277 $14,000
Q4 2021 Feb 14, 2022	SELL	$12.75 - $15.65 $9,664 - $11,862	-758 Reduced 58.44%	539 $7,000
Q3 2021 Nov 15, 2021	BUY	$10.73 - $14.85 $9,657 - $13,365	900 Added 226.7%	1,297 $18,000
Q2 2021 Aug 13, 2021	BUY	$13.0 - $15.67 $5,161 - $6,220	397 New	397 $5,000
Q1 2021 May 12, 2021	SELL	$12.55 - $19.0 $9,399 - $14,231	-749 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$11.35 - $14.5 $8,501 - $10,860	749 New	749 $11,000

Others Institutions Holding IVA

# of Institutions

Shares Held

4.93M

Call Options Held

Put Options Held

View Full List

About Inventiva S.A.

Ticker IVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,134,200
Market Cap $226M
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company als...

More about IVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account